AR019226A1 - USE OF TEXAFIRINES IN MACROPHAGOS MEDIUM DISEASE - Google Patents

USE OF TEXAFIRINES IN MACROPHAGOS MEDIUM DISEASE

Info

Publication number
AR019226A1
AR019226A1 ARP990103250A ARP990103250A AR019226A1 AR 019226 A1 AR019226 A1 AR 019226A1 AR P990103250 A ARP990103250 A AR P990103250A AR P990103250 A ARP990103250 A AR P990103250A AR 019226 A1 AR019226 A1 AR 019226A1
Authority
AR
Argentina
Prior art keywords
texafirines
macrophagos
medium disease
texaphyrins
macrophages
Prior art date
Application number
ARP990103250A
Other languages
Spanish (es)
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of AR019226A1 publication Critical patent/AR019226A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Usos de una texafirina en la preparacion de una composicion farmacéutica para usar en imágenes y/o tratamientos de enfermedades mediadas por macrofagosal hacer sensible los efectos de un agente coterapéutico. Se proveen texafirinas para mejorar la citotoxicidad de agentes terapéuticos en enfermedadesmediadas por macrofagos puesto que se ha demostrado que las texafirinas se acumulan en macrofagos.Uses of a texaphyrin in the preparation of a pharmaceutical composition for use in imaging and / or treatment of macrophageal-mediated diseases make the effects of a therapeutic agent sensitive. Texaphyrins are provided to improve the cytotoxicity of therapeutic agents in diseases mediated by macrophages since it has been shown that texaphyrins accumulate in macrophages.

ARP990103250A 1998-07-06 1999-07-05 USE OF TEXAFIRINES IN MACROPHAGOS MEDIUM DISEASE AR019226A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11050998A 1998-07-06 1998-07-06

Publications (1)

Publication Number Publication Date
AR019226A1 true AR019226A1 (en) 2001-12-26

Family

ID=22333401

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103250A AR019226A1 (en) 1998-07-06 1999-07-05 USE OF TEXAFIRINES IN MACROPHAGOS MEDIUM DISEASE

Country Status (8)

Country Link
EP (1) EP1094840A1 (en)
JP (1) JP2002519390A (en)
KR (1) KR20010079498A (en)
AR (1) AR019226A1 (en)
AU (1) AU4860899A (en)
CA (1) CA2336134A1 (en)
NO (1) NO20010044L (en)
WO (1) WO2000001414A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6163988A (en) * 1995-05-17 2000-12-26 Rockland, Inc. Assembly connectable to an operating arm of a machine for performing work functions
RU2106146C1 (en) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Means to inhibit tumor growth
EP1227844A2 (en) 1999-10-29 2002-08-07 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
US7579338B2 (en) 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
JP2003012547A (en) * 2001-06-27 2003-01-15 Meiji Seika Kaisha Ltd Diagnostic and therapeutic agent for insulin dependent diabetes mellitus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy

Also Published As

Publication number Publication date
AU4860899A (en) 2000-01-24
WO2000001414A1 (en) 2000-01-13
CA2336134A1 (en) 2000-01-13
NO20010044D0 (en) 2001-01-04
NO20010044L (en) 2001-03-01
JP2002519390A (en) 2002-07-02
EP1094840A1 (en) 2001-05-02
KR20010079498A (en) 2001-08-22

Similar Documents

Publication Publication Date Title
CL2004000931A1 (en) CONSUMABLE FILM ADAPTED TO ADHER AND DISSOLVE IN THE ORAL CAVITY THAT INCLUDES A MODIFIED ALMIDON AND A PHARMACEUTICALLY ACTIVE AGENT.
ATE355065T1 (en) THERAPEUTIC COMPOSITIONS CONSISTING OF ANTIHYPOTENSIVES AND ANTIANGIOGENICS
ES2162319T3 (en) USE OF THE CLIOQUINOL CHELATING AGENT FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
BRPI0207961B8 (en) use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds.
DK1259240T3 (en) Agents, such as nicotinamide or CADPR, for the treatment of skin diseases
ES2081110T3 (en) COSMETIC OR PHARMACEUTICAL COMPOSITION, PARTICULARLY DERMATOLOGICAL, INTENDED TO FAVOR SKIN OR HAIR PIGMENTATION, CONTAINING A CYPERUS EXTRACT AND ITS MANUFACTURING PROCEDURE.
ATE232396T1 (en) OXIDATED THYMOSINE BETA 4
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
CO5160321A1 (en) NEW COMPOSITIONS OF TIPRANAVIR AND RITONAVIR
BR0010531A (en) Compositions and uses of et743 for cancer treatment
HUP0100539A2 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
ES2158597T3 (en) BIOAROMATIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING AND USING THEM.
BR0113165A (en) 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
AR019226A1 (en) USE OF TEXAFIRINES IN MACROPHAGOS MEDIUM DISEASE
BR0116972A (en) Methods and devices for administering substances to the intradermal skin layer for systemic absorption
ES2136954T3 (en) USE OF AT LEAST ONE VICHY THERMAL WATER AS A SUBSTANCE ANTAGONIST P.
PT1124566E (en) NON-FERMENTED OSMOTIC LAXATIVE FOR THE TREATMENT AND PREVENTION OF COLORED CANCES
ES2159697T3 (en) USE OF A CGRP ANTAGONIST TO TREAT LIQUES AND PRURITES AND COMPOSITION OBTAINED.
IT1291340B1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES
PT900563E (en) PRODUCTION OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF EDEMA AND VENOUS DISEASES
AR015956A1 (en) COMPOSITIONS OF OROMUCOSAL CYTOKINS AND USES OF THE SAME
SE0001916D0 (en) Novel formulation
MX9805065A (en) Novel bi-aromatic dibenzofuran derivatives and their use in human and veterinary medicine and in cosmetics.
PA8496801A1 (en) PHARMACEUTICAL COMPLEX
ATE258801T1 (en) MATRIX PROTEIN COMPOSITIONS TO INDUCE APOPTOSIS